Organization Details:
| Organization Name: | BIOTECHNOLOGY INDUSTRY RESEARCH ASSISTANCE COUNCIL (BIRAC) |
|---|---|
| Country: | India |
| Contact Person: | |
| Address: |
1st Floor , MTNL Building ,9 , CGO Complex, Lodhi Road, New Delhi-110003 , |
| Contact Details - Email: | birac.dbt@nic.in |
| Phone | +91-11-24389600 |
| Notice Details: | |
| Notice Type | Tender Notice |
| Bidding Type | Other |
| Notice No. | 64179244 |
| Deadline | 2023-04-24 |
| Description | BIRAC ANNOUNCES REQUEST FOR PROPOSALS FOR UNDER NATIONAL BIOPHARMA MISSION LAST DATE :24TH APRIL, 2023 05:00 PM INTRODUCTION Program Overview - NBM This is an Industry-Academia Collaborative Mission for Accelerating Discovery Research to Early Development for Biopharmaceuticals - “Innovate in India (i3) Empowering biotech entrepreneurs & accelerating inclusive innovation”, also referred to as National Biopharma Mission (NBM). Funding agency Department of Biotechnology (DBT) (Program co-funded by World Bank loan) Implementing agency Biotechnology Industry Research Assistance Council (BIRAC) KEY FEATURES OF THE CALL This program is to seek Request for Proposals (RFP) for supporting – Development of products active against sensitive and drug resistant microbial pathogens mentioned in the Indian Priority Pathogen list (mainly, E. coli, Klebsiella Pneumoniae, Acinetobacter baumanii, Pseudomonas aeruginosa, Staphylococcus aureus, carbapenem resistant Enterobacteriaceae (CRE). The products should have established proof of principle including but not limited to the following -: New Chemical Entities or antibiotics from a new class with a novel mechanism of action (first in class), or pre-existing class of drugs (best in class), Repurposed Drugs, Combination with existing drugs Therapeutics which may be broad-spectrum or pathogen-specific antimicrobial Peptides, genetically-engineered antibodies, Immunomodulators, molecules that modulate virulence or pathogenicity, Microbiome modulating agents, bacteriophage therapies Scope of the Call: a) The diagnostic should have demonstrated proof of concept (Completed TRL-3* stage as per BIRAC TRL definitions - https://www.birac.nic.in/desc_new.php?id=44) b) The diagnostic should detect at least one and preferably two of the critical bacterial pathogens as prioritized in the Indian Priority Pathogen List developed by WHO India and the Department of Biotechnology, Govt. of India, and/or test their susceptibility profiles3 c) The areas of support may include validation of prototypes or production technologies; adaptation of products or platform technologies to new applications; manufacturing and scale-up for deployment d) The diagnostic should fulfil at least one or more of the following criteria: 1) Rapid detection test (with test time of <4 hours) that differentially detect and identify species 2) Culture-independent and should focus on direct detection of the target pathogen(s) from primary samples 3) Point-of-Care Tests/kits (POCT) that can be manufactured at large scale WHO CAN APPLY? The proposals can be submitted: a) Solely by Indian Company / LLP/ Non-profit organizations/ Society/ Trusts/ Foundation/Associations/ Government entities/ Institutes/ R&D Organizations/ which is a legal entity OR b) Jointly by Indian Companies/ Non-profit organizations / LLP/ Society/ Trusts/ Foundation/Associations/ Government entities/ Institutes/ R&D Organizations/ OR c) By an Industry-academia consortium of Indian Company/ Non-profit organizations/ LLP/Society/ Trusts/ Foundation/ Association/ Government entities/ Institutes/ R&D Organizations a) Indian Start-up companies in collaboration with Industry/Academia/research institutes/ are specia |
| Soft Copy | Soft copy |
| Documents | Download documents |